IGF1RES
MCID: INS024
MIFTS: 80

Insulin-Like Growth Factor I (IGF1RES)

Categories: Ear diseases, Endocrine diseases, Genetic diseases, Mental diseases, Metabolic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Insulin-Like Growth Factor I

MalaCards integrated aliases for Insulin-Like Growth Factor I:

Name: Insulin-Like Growth Factor I 56
Insulin-Like Growth Factor I Deficiency 56 52 73 36 29 6 71
Igf1 Deficiency 56 52 73 54
Growth Retardation with Deafness and Mental Retardation Due to Igf1 Deficiency 56 13 39
Insulin-Like Growth Factor I, Resistance to 56 13 71
Insulin-Like Growth Factor 1 Resistance to 52 29 6
Growth Retardation with Sensorineural Deafness and Mental Retardation 56 52
Growth Delay Due to Insulin-Like Growth Factor I Resistance 58 36
Igf-I Resistance 56 54
Igf1res 56 73
Growth Delay Due to Insulin-Like Growth Factor Type 1 Deficiency 58
Growth Delay-Deafness-Intellectual Disability Syndrome 58
Primary Insulin-Like Growth Factor Deficiency 58
Insulin-Like Growth Factor 1, Resistance to 39
Resistance to Insulin-Like Growth Factor I 73
Somatomedin, End-Organ Insensitivity to 56
Insulin-Like Growth Factor 1 Resistance 73
Somatomedin End-Organ Insensitivity to 52
End-Organ Insensitivity to Somatomedin 73
Somatomedin-C, Resistance to 56
Somatomedin-C Resistance to 52
Resistance to Somatomedin-C 73
Resistance to Igf-1 58
Igf-1 Resistance 52
Igf-1 Deficiency 58
Igf1 Resistance 73
Somatomedin-C 56

Characteristics:

Orphanet epidemiological data:

58
growth delay due to insulin-like growth factor type 1 deficiency
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Infancy,Neonatal;
growth delay due to insulin-like growth factor i resistance
Inheritance: Autosomal dominant,Autosomal recessive; Age of onset: Infancy,Neonatal;

OMIM:

56
Inheritance:
autosomal recessive
autosomal dominant

Miscellaneous:
onset in utero
dominant and recessive patients have iugr, short stature, and microcephaly
heterozygous relatives of some biallelic patients appear to be unaffected


HPO:

31
insulin-like growth factor i:
Inheritance autosomal dominant inheritance autosomal recessive inheritance
Onset and clinical course congenital onset

insulin-like growth factor i deficiency:
Inheritance autosomal recessive inheritance
Onset and clinical course congenital onset


Classifications:

Orphanet: 58  
Rare endocrine diseases


Summaries for Insulin-Like Growth Factor I

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 73273 Definition Growth delay due to IGF-I resistance is characterised by variable intrauterine and postnatal growth retardation and elevated serum IGF-I levels. Addition features include variable degrees of intellectual deficit, microcephaly and dysmorphism (broad nasal bridge and tip, smooth philtrum, thin upper and everted lower lips, short fingers, clinodactyly, wide-set nipples and pectus excavatum). Epidemiology Prevalence is unknown. Etiology IGF-I resistance may be caused by a variety of genetic defects: ring chromosome 15, distal heterozygous 15q deletions encompassing the IGF1R gene (15q26.3), or IGF1R gene mutations . Intellectual deficit is pronounced in patients with ring chromosome 15 but varies depending on the size of the deletion and on the functions of other deleted genes in patients with 15q deletions. Partial IGF-I insensitivity due to IGF1R haploinsufficiency has been reported in one patient with a small deletion encompassing one allele of the IGF1R gene and was characterised by small size for gestational age, persistent growth failure that improved considerably with GH therapy, and the absence of intellectual deficit. IGF1R mutations have been described in six patients so far and were associated with variable growth delay and degrees of intellectual deficit. Diagnostic methods Diagnosis relies on karyotyping for detection of ring chromosome 15, detection of small deletions encompassing IGF1R and detection of IGF1R mutations by sequence variation screening methods or by direct sequencing of the 21 IGF1R exons and their intron -exon junctions. Differential diagnosis The differential diagnosis should include bio-inactive IGF-I resulting in IGF-I deficiency (see this term). Measurement of IGF-I levels can be used for diagnosis but circulating levels of IGF-I may vary over time for the same patient and may not be elevated in case of poor nutritional status. Antenatal diagnosis Prenatal diagnosis has not been reported and is complicated by the variable expressivity (even within the same family) of some of the reported mutations, especially in terms of their impact on intellectual development. Genetic counseling In all but one of these patients, the mutations were heterozygous and transmitted as an autosomal dominant trait . Affected families should be offered genetic counselling and informed of a 50% risk of recurrence for dominant inheritance and of a 25% risk of recurrence for recessive transmission. Management and treatment Management involves nutritional and developmental support. Although deafness has not yet been reported in patients with IGF-I resistance, it is present in some patients with IGF-I deficiency (caused by mutations in the gene encoding the IGF1R ligand, IGFI ). As a result, screening for deafness should be proposed for all patients with IGF-I resistance. Some patients with IGF-I resistance show increased growth velocity with recombinant GH therapy while others show no response. Prognosis Prognosis varies depending on the underlying molecular anomaly. Visit the Orphanet disease page for more resources.

MalaCards based summary : Insulin-Like Growth Factor I, also known as insulin-like growth factor i deficiency, is related to acid-labile subunit deficiency and laron syndrome, and has symptoms including agitation An important gene associated with Insulin-Like Growth Factor I is IGF1R (Insulin Like Growth Factor 1 Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Oocyte meiosis. The drugs Clonidine and Insulin aspart have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and liver, and related phenotypes are failure to thrive and delayed skeletal maturation

OMIM : 56 Patients with mutations in the receptor for insulin-like growth factor I show intrauterine growth retardation and postnatal growth failure, resulting in short stature and microcephaly. Other features may include delayed bone age, developmental delay, and dysmorphic features. (270450)

KEGG : 36 Insulin-like growth factor I (IGF1) deficiency due to mutations in IGF1 gene is an autosomal recessive disorder, characterized by severe prenatal and postnatal growth failure, sensorineural deafness, and mental retardation. Patients have the extremely low IGF1 circulating levels, and respond to treatment with IGF1.

UniProtKB/Swiss-Prot : 73 Insulin-like growth factor 1 resistance: A disorder characterized by intrauterine growth retardation, poor postnatal growth and increased plasma IGF1 levels.
Insulin-like growth factor I deficiency: Autosomal recessive disorder characterized by growth retardation, sensorineural deafness and mental retardation.

Wikipedia : 74 Insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a hormone similar in molecular... more...

Related Diseases for Insulin-Like Growth Factor I

Diseases related to Insulin-Like Growth Factor I via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 804)
# Related Disease Score Top Affiliating Genes
1 acid-labile subunit deficiency 33.6 IGFBP3 IGF2 IGF1
2 laron syndrome 33.2 IGFBP3 IGFBP2 IGFBP1 IGF2 IGF1 GHR
3 nutritional deficiency disease 31.8 IGFBP3 IGFBP1 IGF1 GH1
4 bone resorption disease 31.7 INS IGF1 AKT1
5 acromegaly 31.6 INS IGFBP3 IGFBP2 IGFBP1 IGF2 IGF1
6 microvascular complications of diabetes 5 31.6 INS IGFBP1 IGF1 AKT1
7 osteogenic sarcoma 31.5 IGFBP6 IGF2 IGF1R IGF1
8 hypopituitarism 31.4 INS IGFBP3 IGF1 GHR GH1
9 isolated growth hormone deficiency 31.4 IGF1 GHR GH1
10 hypothyroidism 31.4 INS IGFBP3 IGF1 GHR GH1
11 pre-eclampsia 31.4 INS IGFBP3 IGFBP1 IGF2 IGF1
12 microvascular complications of diabetes 1 31.3 INS IGFBP3 IGF1
13 exudative vitreoretinopathy 1 31.3 INS IGFBP3 IGF1 AKT1
14 hyperprolactinemia 31.3 INS IGF1 GH1
15 hyperglycemia 31.2 IRS1 INSR INS IGF1R IGF1 GH1
16 mammographic density 31.2 IGFBP3 IGF1
17 central precocious puberty 31.2 IGF1 GH1
18 neurofibromatosis, type ii 31.1 INS IGF1 AKT1
19 glucose intolerance 31.1 IRS1 INSR INS IGFBP3 IGFBP1 IGF1
20 turner syndrome 31.1 INS IGFBP3 IGFBP1 IGF2 IGF1 GHR
21 colorectal adenoma 31.1 INS IGFBP3 IGF2 IGF1
22 anovulation 31.1 INS IGFBP3 IGFBP1 IGF1
23 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 31.1 INSR INS IGFBP3 IGF1
24 polycystic ovary syndrome 31.1 IRS1 INSR INS IGFBP3 IGFBP1 IGF2
25 fatty liver disease 31.1 IRS1 INSR INS AKT1
26 acanthosis nigricans 31.1 INSR INS IGF1R IGF1 GH1
27 donohue syndrome 31.1 IRS1 INSR INS IGFBP3 IGF1R IGF1
28 hyperinsulinism 31.1 IRS1 INSR INS IGFBP3 IGFBP1 IGF2
29 diffuse idiopathic skeletal hyperostosis 31.0 INS IGFBP3 IGF1
30 anorexia nervosa 31.0 INS IGFBP3 IGFBP2 IGFBP1 IGF1 GHR
31 gestational diabetes 31.0 IRS1 INSR INS IGFBP1 IGF2
32 pituitary adenoma 1, multiple types 31.0 IGFBP3 IGF1 GH1
33 fasting hypoglycemia 31.0 INSR IGF2 IGF1
34 pituitary gland disease 31.0 INS IGFBP3 IGF1 GHR GH1
35 ewing sarcoma 30.9 IGFBP3 IGF2 IGF1R IGF1 AKT1
36 hyperandrogenism 30.9 INSR INS IGFBP3 IGFBP1 IGF2 IGF1
37 hyperostosis 30.9 IGFBP3 IGF1 AKT1
38 diabetes mellitus, insulin-dependent 30.9 INSR INS IGFBP3 IGFBP2 IGFBP1 IGF2
39 non-alcoholic fatty liver disease 30.9 IRS1 INSR INS AKT1
40 uremia 30.9 INS GHR GH1
41 rhabdomyosarcoma 30.9 IRS1 IGFBP6 IGF2 IGF1R IGF1 AKT1
42 pituitary hormone deficiency, combined, 2 30.9 INS IGFBP3 IGF1 GHR GH1
43 fetal macrosomia 30.9 INSR INS IGFBP3 IGF2 IGF1
44 craniopharyngioma 30.8 INS IGF1 GH1
45 secondary adrenal insufficiency 30.8 INS IGFBP3 IGF1
46 hypothalamic disease 30.8 INS IGF1 GH1
47 hypoglycemia 30.8 INSR INS IGFBP3 IGFBP2 IGFBP1 IGF2
48 breast disease 30.7 IGFBP3 IGFBP1 IGF2 IGF1
49 retinal vascular disease 30.7 INS IGF1 AKT1
50 overnutrition 30.7 IRS1 INS IGF1 AKT1

Graphical network of the top 20 diseases related to Insulin-Like Growth Factor I:



Diseases related to Insulin-Like Growth Factor I

Symptoms & Phenotypes for Insulin-Like Growth Factor I

Human phenotypes related to Insulin-Like Growth Factor I:

58 31 (show top 50) (show all 86)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 failure to thrive 58 31 hallmark (90%) Very frequent (99-80%) HP:0001508
2 delayed skeletal maturation 58 31 frequent (33%) Frequent (79-30%),Very frequent (99-80%) HP:0002750
3 abnormal facial shape 58 31 hallmark (90%) Very frequent (99-80%) HP:0001999
4 short stature 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0004322
5 intrauterine growth retardation 58 31 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0001511
6 microcephaly 58 31 hallmark (90%) Very frequent (99-80%),Frequent (79-30%) HP:0000252
7 intellectual disability, mild 58 31 hallmark (90%) Very frequent (99-80%) HP:0001256
8 attention deficit hyperactivity disorder 58 31 hallmark (90%) Very frequent (99-80%) HP:0007018
9 congenital sensorineural hearing impairment 58 31 hallmark (90%) Very frequent (99-80%) HP:0008527
10 severe postnatal growth retardation 58 31 hallmark (90%) Very frequent (99-80%) HP:0008850
11 insulin resistance 58 31 hallmark (90%) Very frequent (99-80%) HP:0000855
12 small for gestational age 58 31 hallmark (90%) Very frequent (99-80%) HP:0001518
13 severe intrauterine growth retardation 58 31 hallmark (90%) Very frequent (99-80%) HP:0008846
14 bilateral sensorineural hearing impairment 58 31 hallmark (90%) Very frequent (99-80%) HP:0008619
15 prelingual sensorineural hearing impairment 58 31 hallmark (90%) Very frequent (99-80%) HP:0000399
16 pectus excavatum 58 31 frequent (33%) Frequent (79-30%) HP:0000767
17 clinodactyly 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0030084
18 intellectual disability 58 31 frequent (33%) Very frequent (99-80%),Frequent (79-30%) HP:0001249
19 wide nasal bridge 58 31 frequent (33%) Frequent (79-30%) HP:0000431
20 micrognathia 58 31 frequent (33%) Frequent (79-30%) HP:0000347
21 smooth philtrum 58 31 frequent (33%) Frequent (79-30%) HP:0000319
22 osteoporosis 58 31 frequent (33%) Frequent (79-30%) HP:0000939
23 broad nasal tip 58 31 frequent (33%) Frequent (79-30%) HP:0000455
24 delayed eruption of teeth 58 31 frequent (33%) Frequent (79-30%) HP:0000684
25 short palm 58 31 frequent (33%) Frequent (79-30%) HP:0004279
26 everted lower lip vermilion 58 31 frequent (33%) Frequent (79-30%) HP:0000232
27 wide intermamillary distance 58 31 very rare (1%) Frequent (79-30%) HP:0006610
28 motor delay 58 31 occasional (7.5%) Occasional (29-5%),Frequent (79-30%) HP:0001270
29 hypogonadism 58 31 frequent (33%) Frequent (79-30%) HP:0000135
30 clinodactyly of the 5th finger 58 31 frequent (33%) Frequent (79-30%) HP:0004209
31 thin vermilion border 58 31 frequent (33%) Frequent (79-30%) HP:0000233
32 neonatal hyperbilirubinemia 58 31 frequent (33%) Frequent (79-30%) HP:0003265
33 small placenta 58 31 frequent (33%) Frequent (79-30%) HP:0006266
34 cafe-au-lait spot 58 31 occasional (7.5%) Occasional (29-5%) HP:0000957
35 prominent forehead 58 31 occasional (7.5%) Occasional (29-5%) HP:0011220
36 hypoglycemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001943
37 concave nasal ridge 58 31 occasional (7.5%) Occasional (29-5%) HP:0011120
38 low posterior hairline 58 31 occasional (7.5%) Occasional (29-5%) HP:0002162
39 myopia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000545
40 low anterior hairline 58 31 occasional (7.5%) Occasional (29-5%) HP:0000294
41 truncal obesity 58 31 occasional (7.5%) Occasional (29-5%) HP:0001956
42 single transverse palmar crease 58 31 occasional (7.5%) Occasional (29-5%) HP:0000954
43 congenital bilateral ptosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0007911
44 ptosis 58 31 Occasional (29-5%) HP:0000508
45 sensorineural hearing impairment 58 31 Very frequent (99-80%) HP:0000407
46 hyperactivity 58 31 Very frequent (99-80%) HP:0000752
47 short attention span 58 31 Very frequent (99-80%) HP:0000736
48 low-set ears 31 HP:0000369
49 high palate 31 HP:0000218
50 diabetes mellitus 31 HP:0000819

Symptoms via clinical synopsis from OMIM:

56
Skeletal Hands:
clinodactyly
short fingers
small hands

Growth Height:
short stature

Head And Neck Head:
microcephaly

Head And Neck Face:
triangular face
long, smooth philtrum
facial dysmorphism (in some patients)
receding hairline
progeroid appearance (in some recessive patients)
more
Head And Neck Nose:
broad nasal bridge

Growth Weight:
low weight

Chest External Features:
pectus excavatum (rare)

Head And Neck Ears:
low-set ears (recessive)

Head And Neck Teeth:
delayed eruption of dentition (recessive)
small opalescent teeth (recessive)
brittle teeth (recessive)
eroded teeth (recessive)

Cardiovascular Heart:
patent foramen ovale (recessive)
atrial septal defect (recessive)
ventricular septal defect (recessive)

Skin Nails Hair Skin:
axillary acanthosis nigricans (recessive)

Muscle Soft Tissue:
reduced subcutaneous fat (recessive)
truncal obesity (recessive)
lipodystrophy (recessive)

Endocrine Features:
elevated baseline insulin (recessive)
diabetes mellitus, type 2 (in some heterozygous adults)
diabetes mellitus, type 1 (in 1 recessive adolescent patient)

Neurologic Central Nervous System:
global developmental delay
delayed motor development
mental retardation
speech delay
developmental delay, mild
more
Growth Other:
intrauterine growth retardation
poor growth

Neurologic Behavioral Psychiatric Manifestations:
agitation
anxious affect
obsessive tendencies

Head And Neck Mouth:
thin upper lip
fleshy lower lip
high-arched palate (recessive)
small mouth (recessive)

Skeletal:
delayed bone age

Skeletal Feet:
small feet
sandal gap (recessive)

Chest Breasts:
widely spaced nipples (rare)

Head And Neck Eyes:
deep-set eyes (recessive)
strabismus (recessive)
synophrys (recessive)
arched eyebrows (recessive)
upslanting palpebral fissures (recessive)
more
Head And Neck Neck:
pterygium colli (recessive)

Cardiovascular Vascular:
narrowing of pulmonary branch arteries (recessive)
continuation of inferior vena cava to azygos vein (recessive)

Skin Nails Hair Hair:
sparse scalp hair (recessive)

Voice:
high-pitched voice (recessive)

Laboratory Abnormalities:
increased serum insulin-like growth factor-1 (igf1, )
increased or normal serum growth hormone (gh, )

Clinical features from OMIM:

270450 608747

UMLS symptoms related to Insulin-Like Growth Factor I:


agitation

GenomeRNAi Phenotypes related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

26 (show all 40)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.76 ITGB3
2 Decreased viability GR00221-A-1 10.76 AKT1 AKT2 IGF1R INSR IRS1
3 Decreased viability GR00221-A-2 10.76 AKT1 IGF1R INSR IRS1 ITGAV ITGB3
4 Decreased viability GR00221-A-3 10.76 AKT1 AKT2 IGF1R INSR
5 Decreased viability GR00221-A-4 10.76 AKT1 AKT2 INSR ITGB3
6 Decreased viability GR00301-A 10.76 AKT2 IGF1R
7 Decreased viability GR00342-S-2 10.76 IGF1R IRS1
8 Decreased viability GR00342-S-3 10.76 AKT2 IRS1
9 Decreased viability GR00381-A-1 10.76 ITGAV
10 Decreased viability GR00402-S-2 10.76 AKT1 AKT2 IGF1R INSR IRS1 ITGAV
11 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.21 GH1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.21 AKT2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.21 IGF1R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.21 GH1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.21 IGF1R
16 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.21 GH1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.21 GH1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.21 AKT2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.21 AKT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.21 GH1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.21 IGF1R
22 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.21 AKT1 IGF1R
23 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.21 INSR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.21 IGF1R
25 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.21 GH1 IGF1R
26 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.21 AKT2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.21 AKT1 INSR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.21 IGF1R
29 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.21 IGF1R
30 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.21 AKT1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.21 GH1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.21 AKT1 AKT2 GH1 IGF1R INSR
33 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.21 AKT1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.21 IGF1R
35 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.21 AKT1 AKT2 IGF1R INSR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.21 GH1
37 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.85 AKT2 IGF1R IRS1 ITGA6 ITGAV ITGB3
38 Increased cell death HMECs cells GR00103-A-0 9.8 IGF1R IGFBP4 IGFBP6 INS INSR IRS1
39 Increased cell viability after pRB stimulation GR00230-A-1 9.46 AKT1 AKT2 IGF1R INSR
40 Reduced mammosphere formation GR00396-S 9.17 GHR IGF1 IGF1R IGF2 IGFBP3 IGFBP6

MGI Mouse Phenotypes related to Insulin-Like Growth Factor I:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.45 AKT1 AKT2 GHR IGF1 IGF1R IGF2
2 cellular MP:0005384 10.43 AKT1 AKT2 GHR IGF1 IGF1R IGF2
3 endocrine/exocrine gland MP:0005379 10.43 AKT1 AKT2 GHR IGF1 IGF1R IGF2
4 cardiovascular system MP:0005385 10.4 AKT1 GHR IGF1 IGF1R IGF2 IGFBP2
5 homeostasis/metabolism MP:0005376 10.4 AKT1 AKT2 GHR IGF1 IGF1R IGF2
6 immune system MP:0005387 10.39 AKT1 AKT2 GHR IGF1 IGF1R IGF2
7 hematopoietic system MP:0005397 10.38 AKT1 AKT2 GHR IGF1 IGF1R IGF2
8 adipose tissue MP:0005375 10.34 AKT1 AKT2 GHR IGF1 IGF1R IGFBP3
9 mortality/aging MP:0010768 10.25 AKT1 AKT2 GHR IGF1 IGF1R IGF2
10 muscle MP:0005369 10.25 AKT1 AKT2 GHR IGF1 IGF1R IGF2
11 liver/biliary system MP:0005370 10.23 AKT1 AKT2 GHR IGF1R IGF2 IGFBP1
12 embryo MP:0005380 10.22 AKT1 GHR IGF1R IGF2 INS ITGA6
13 integument MP:0010771 10.19 AKT1 AKT2 GHR IGF1 IGF1R IGF2
14 digestive/alimentary MP:0005381 10.18 IGF1R IGF2 INS INSR ITGA6 ITGAV
15 nervous system MP:0003631 10.1 AKT1 AKT2 GHR IGF1 IGF1R IGF2
16 limbs/digits/tail MP:0005371 10.08 GHR IGF1 IGF1R IGF2 IGFBP3 IRS1
17 renal/urinary system MP:0005367 9.96 GHR IGF1 IGF2 IGFBP2 INS INSR
18 neoplasm MP:0002006 9.91 AKT1 AKT2 IGF1 IGF1R ITGA6 ITGAV
19 reproductive system MP:0005389 9.85 AKT1 AKT2 GHR IGF1 IGF1R IGF2
20 respiratory system MP:0005388 9.61 AKT1 AKT2 IGF1 IGF1R IGF2 INSR
21 skeleton MP:0005390 9.36 AKT1 AKT2 GHR IGF1 IGF1R IGF2

Drugs & Therapeutics for Insulin-Like Growth Factor I

Drugs for Insulin-Like Growth Factor I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Insulin aspart Approved Phase 4 116094-23-6 16132418
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Cabergoline Approved Phase 4 81409-90-7 54746
5
Octreotide Approved, Investigational Phase 4 83150-76-9 6400441 383414
6
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
7
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
8 Antihypertensive Agents Phase 4
9 Adrenergic Agonists Phase 4
10 Sympatholytics Phase 4
11 Adrenergic alpha-2 Receptor Agonists Phase 4
12 Adrenergic Agents Phase 4
13 Insulin, Globin Zinc Phase 4
14 insulin Phase 4
15 Neurotransmitter Agents Phase 4
16 Autonomic Agents Phase 4
17 Dopamine Agents Phase 4
18 Dopamine agonists Phase 4
19 Antiparkinson Agents Phase 4
20 Gastrointestinal Agents Phase 4
21 Sympathomimetics Phase 4
22 Protective Agents Phase 4
23 Antineoplastic Agents, Hormonal Phase 4
24 Fertility Agents Phase 4
25 Fenugreek seed meal Phase 4
26 Fenugreek Phase 4
27
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
28
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
29
Ethinyl Estradiol Approved Phase 2, Phase 3 57-63-6 5991
30
Racepinephrine Approved Phase 2, Phase 3 329-65-7 838
31
Levonorgestrel Approved, Investigational Phase 2, Phase 3 17489-40-6, 797-63-7 13109
32
Pasireotide Approved Phase 3 396091-73-9 9941444
33
Insulin glargine Approved Phase 3 160337-95-1
34
Insulin detemir Approved Phase 3 169148-63-4 5311023
35
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
36
Milk thistle Approved, Experimental, Investigational Phase 2, Phase 3 65666-07-1
37
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
38
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
39
Sodium citrate Approved, Investigational Phase 3 68-04-2
40
Tamoxifen Approved Phase 3 10540-29-1 2733526
41 Papaya Approved Phase 2, Phase 3
42
Polyestradiol phosphate Approved Phase 3 28014-46-2
43
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
44
tannic acid Approved Phase 3 1401-55-4
45
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
46
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
47
Mecasermin Approved, Investigational Phase 3 68562-41-4
48
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
49
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
50
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2

Interventional clinical trials:

(show top 50) (show all 111)
# Name Status NCT ID Phase Drugs
1 Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia Telangiectasia Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
2 Mechanisms of Low Protein Diet Supplemented With α-ketoacids on Autophagy and Improving Muscle Wasting in Chronic Kidney Disease: the Role of Autophagy in Muscle Wasting Unknown status NCT02568020 Phase 4 keto-amino acids
3 Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients Completed NCT01209403 Phase 4 Glucose-infusion;Glucose-insulin infusion
4 An Open-label, Two-step, Multicenter European Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Not Adequately Controlled by Conventional Regimen Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
5 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
6 Effect of Growth Hormone Replacement Therapy on Cardiovascular Risk Factors in Adult Patients With Severe Growth Hormone Deficiency: Association With IGF-I Concentration Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
7 Efficacy of Growth Hormone Supplementation With Gonadotrophins in IVF/ICSI for Poor Responders; a Randomized Controlled Trial Completed NCT03759301 Phase 4 Growth Hormones Somatropin Recombinant;Placebo saline solution
8 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
9 The Effects of Weekly Administration of 40 mg Pegvisomant or Placebo on Quality of Life and Insulin Sensitivity in Acromegalic Patients With Normal IGF-I Concentrations During Long-Term Treatment With Long-Acting Somatostatin Analogs Completed NCT00642720 Phase 4 Pegvisomant
10 Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa Completed NCT01823822 Phase 2, Phase 3
11 Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa Completed NCT00310791 Phase 2, Phase 3 Hormone replacement therapy (estrogen/progestin);Dehydroepiandrosterone (DHEA)
12 A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3 Pasireotide;Octreotide
13 More Favorable Metabolic Impact of Three-times-weekly Versus Daily Growth Hormone (GH) Treatment in naïve GH-deficient Children Completed NCT03033121 Phase 3 Growth Hormone
14 Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on IGFBP-1 Production and Serum IGF-I in Subjects With Type 1 Diabetes Mellitus: An Open-label, Randomised, Triple Cross-over Trial Completed NCT01461616 Phase 3 NPH;Detemir;Glargine
15 Phase 2-3 Study of Silymarin on Cisplatin Induced Nephrotoxicity Completed NCT01829178 Phase 2, Phase 3 Silymarin;Placebo;chemotherapy
16 Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With Primary IGF-1 Deficiency: A Multi-Center, Open Label, Concentration-Controlled Study Completed NCT00125190 Phase 2, Phase 3 rhIGF-1 (mecasermin) for a period of 86 weeks
17 Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Prepubertal Children With Growth Failure Associated With Primary IGF-1 Deficiency: A Phase 3, Randomized, Open Label, Observation-Controlled, Multicenter, Parallel-Dose Comparison Trial Completed NCT00125164 Phase 3 rhIGF-1 (mecasermin, Tercica, Inc.)
18 A RANDOMIZED TRIAL OF ANTIESTROGEN THERAPY VERSUS COMBINED ANTIESTROGEN AND OCTREOTIDE LAR THERAPY IN THE ADJUVANT TREATMENT OF BREAST CANCER IN POST-MENOPAUSAL WOMEN Completed NCT00002864 Phase 3 octreotide acetate;tamoxifen citrate
19 Phase III, Multi-Center, Open, 12-Week, Follow-up Safety and Efficacy Study of Serostim® in Subjects With Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome (HARS) Completed NCT01077960 Phase 3
20 Molecular and Clinical Effects of Green Tea and Fermented Papaya Preparation on Diabetes and Cardiovascular Diseases Completed NCT01248143 Phase 2, Phase 3
21 A Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS) Completed NCT00109733 Phase 3
22 Effects of Anorexia Nervosa on Peak Bone Mass Active, not recruiting NCT01301183 Phase 3 RhIGF-1 with transdermal 17-beta estradiol;Placebo and transdermal 17-beta estradiol
23 Recombinant Human Insulin-Like Growth Factor-1 (IGF-1) Treatment of Children With Growth Failure Associated With Primary IGF-1 Deficiency: An Open-Label, Multi-Center, Extension Study Terminated NCT00330668 Phase 3 rh IGF-1 (mecasermin)
24 A Randomized Placebo-Controlled Trial of Dehydroepiandrosterone (DHEA) Treatment for Two Months Before Starting Ovulation Induction for in Vitro Fertilization (IVF) Terminated NCT00419913 Phase 2, Phase 3
25 Effect of Increlex® on Children With Crohn Disease Terminated NCT00764699 Phase 2, Phase 3 rhIGF (Increlex)
26 A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Safety and Efficacy Endpoints After Administration of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) for 24 Weeks in Adults With Myotonic Dystrophy Type 1 Unknown status NCT00577577 Phase 2 rhIGF-I/rhIGFBP-3;placebo
27 A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With High-Risk Endometrial Cancer After Standard Surgical Staging Unknown status NCT01041027 Phase 2 Paclitaxel;Carboplatin
28 A Prospective, Randomized Trial of Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas Unknown status NCT00993356 Phase 2 Preoperative lanreotide treatment
29 Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism Completed NCT00004700 Phase 2 insulin-like growth factor I
30 A 64-Week (12-week Core Phase and 52-week Safety Extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency Completed NCT01811576 Phase 2 TV-1106;Recombinant human growth hormone
31 Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents Completed NCT00516386 Phase 1, Phase 2 RhIGF-1
32 Glucocorticoid Induced Inhibition of IGF-I Activity: Exploring Underlying Mechanisms. Completed NCT01762540 Phase 2 Glucocorticoids;Calcium Supplement
33 Phase II Clinical Trial to Determine if Polyphenon E Inhibits c-Met Signaling and Activation of Pathways Contributing to Breast Cancer Progression Completed NCT00676793 Phase 2 Polyphenon E
34 Green Tea Extract and Prostate Cancer Completed NCT00676780 Phase 2 Polyphenon E (EGCG)
35 GHRH: Cognition in Aging and MCI Completed NCT00257712 Phase 2 TH9507 human growth hormone releasing hormone (GHRH)
36 Bone Response to Soy Isoflavones in Women Completed NCT00043745 Phase 2
37 A Randomized Phase 2 Open-Label Study of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Disease Progression on Prior Platinum-Based Chemotherapy Completed NCT00617734 Phase 2
38 A Randomized Phase II Prevention Trial in Subjects at High Risk for Hormone Non-responsive Breast Cancer Completed NCT01500577 Phase 2 nimesulide;Simvastatin
39 A Double-Blind Placebo-Controlled Crossover Trial of Insulin-Like Growth Factor-1 (IGF-1) in Children and Adolescents With 22q13 Deletion Syndrome(Phelan-McDermid Syndrome) Recruiting NCT01525901 Phase 2 Insulin-Like Growth Factor-1 (IGF-1);Normal saline
40 A Phase 2, Open-Label, Multicenter, Clinical Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 in Children With Growth Failure Due to Noonan Syndrome Terminated NCT00351221 Phase 2 rhIGF-1/rhIGFBP-3
41 A Randomized Phase II Clinical Trial Investigating Irinotecan Plus Cetuximab With or Without Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody (IMC-A12) for the Treatment of Patients With Metastatic K-Ras Wild Type Carcinoma of the Colon or Rectum That Has Progressed on Oxaliplatin and Bevacizumab Given as First-Line Therapy Terminated NCT00845039 Phase 2 Irinotecan
42 Six Month Treatment of GHRH in the Elderly Terminated NCT00807365 Phase 2 GHRH
43 Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 rhIGF-1) Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency: A Six-year, Randomized, Multi-center, Open-label, Parallel-group, Active Treatment Controlled, Dose Selection Trial Terminated NCT00572156 Phase 2 NutropinAq® (Somatropin [rDNA origin]);Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]);Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]);Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
44 Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 Administered Every Other Week in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available Completed NCT00785941 Phase 1
45 Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available Completed NCT00785538 Phase 1
46 Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial Completed NCT01372644 Phase 1 SOM 230 / Pasireotide
47 Impact of Estradiol Addback on Somatostatin Rebound in Older Men Completed NCT01862835 Phase 1 Degarelix;Testosterone;Anastrozole;Estrogen patch
48 Effects of Growth Hormone (GH) on Parameters of the Nitric Oxide (NO) Pathway Completed NCT00470002 Phase 1 Somatropin
49 A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma Completed NCT00001436 Phase 1 OncoLAR® (Registered Trademark);tamoxifen
50 A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT00880282 Phase 1 temsirolimus

Search NIH Clinical Center for Insulin-Like Growth Factor I

Genetic Tests for Insulin-Like Growth Factor I

Genetic tests related to Insulin-Like Growth Factor I:

# Genetic test Affiliating Genes
1 Insulin-Like Growth Factor I Deficiency 29 IGF1
2 Insulin-Like Growth Factor 1 Resistance to 29 IGF1R

Anatomical Context for Insulin-Like Growth Factor I

MalaCards organs/tissues related to Insulin-Like Growth Factor I:

40
Bone, Breast, Liver, Pituitary, Prostate, Thyroid, Skeletal Muscle

Publications for Insulin-Like Growth Factor I

Articles related to Insulin-Like Growth Factor I:

(show top 50) (show all 14247)
# Title Authors PMID Year
1
Clinical and functional characteristics of the human Arg59Ter insulin-like growth factor i receptor (IGF1R) mutation: implications for a gene dosage effect of the human IGF1R. 56 6 61 54
16569742 2006
2
A familial insulin-like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. 6 61 56
17264177 2007
3
IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. 6 61 56
14657428 2003
4
A New Homozygous IGF1R Variant Defines a Clinically Recognizable Incomplete Dominant form of SHORT Syndrome. 56 6
26252249 2015
5
Homozygous mutation of the IGF1 receptor gene in a patient with severe pre- and postnatal growth failure and congenital malformations. 6 56
23045302 2013
6
Severe short stature caused by novel compound heterozygous mutations of the insulin-like growth factor 1 receptor (IGF1R). 6 56
22130793 2012
7
Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. 56 6
15928254 2005
8
A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor I receptor. 61 54 56
16757531 2006
9
Decreased insulin-like growth factor I receptor expression and function in immortalized African Pygmy T cells. 61 54 56
8964861 1996
10
An insulin-like growth factor-I receptor defect associated with short stature and impaired carbohydrate homeostasis in an Italian pedigree. 61 56
21811077 2011
11
Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. 61 6
15769976 2005
12
A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. 6 54
14684690 2003
13
Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. 61 6
8857020 1996
14
Short stature with normal growth hormone and elevated IGF-I. 61 56
1396882 1992
15
Measurement of insulin-like growth factor I (IGF-I) responsiveness of fibroblasts of children with short stature: identification of a patient with IGF-I resistance. 56 61
3818890 1987
16
Stimulation by somatomedin-C of aminoisobutyric acid uptake in human fibroblasts: a possible test for cellular responsiveness to somatomedin. 61 56
6358242 1984
17
Endogenous insulin-like growth factor (IGF) binding proteins cause IGF-1 resistance in cultured fibroblasts from a patient with short stature. 56
1707060 1991
18
Pseudopituitary dwarfism due to resistance to somatomedin: a new syndrome. 56
6088245 1984
19
Dwarfism associated with normal serum growth hormone and increased bioassayable, receptorassayable, and immunoassayable somatomedin. 56
6987254 1980
20
A heterozygous mutation of the insulin-like growth factor-I receptor causes retention of the nascent protein in the endoplasmic reticulum and results in intrauterine and postnatal growth retardation. 54 61
20357178 2010
21
Heterozygous mutation within a kinase-conserved motif of the insulin-like growth factor I receptor causes intrauterine and postnatal growth retardation. 61 54
20103656 2010
22
Oxidative stress inhibits insulin-like growth factor-I induction of chondrocyte proteoglycan synthesis through differential regulation of phosphatidylinositol 3-Kinase-Akt and MEK-ERK MAPK signaling pathways. 61 54
19762915 2009
23
Mechanisms of impaired growth: effect of steroids on bone and cartilage. 61 54
19940493 2009
24
Lack of effect of IGF-I on the glomerular filtration rate in non-diabetic patients with advanced chronic kidney disease. 61 54
19046909 2009
25
Longitudinal changes in insulin-like growth factor-I, insulin sensitivity, and secretion from birth to age three years in small-for-gestational-age children. 54 61
16912131 2006
26
Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. 54 61
16914728 2006
27
Signaling through the small G-protein Cdc42 is involved in insulin-like growth factor-I resistance in aging articular chondrocytes. 61 54
16779831 2006
28
Cachexia: pathophysiology and clinical relevance. 54 61
16600922 2006
29
Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. 61 54
15790724 2005
30
Proinflammatory cytokine impairment of insulin-like growth factor I-induced protein synthesis in skeletal muscle myoblasts requires ceramide. 61 54
15256490 2004
31
Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. 54 61
12006367 2002
32
IGF-I resistance and Turner's syndrome. 54 61
11220703 2001
33
Normal intelligence with severe insulin-like growth factor I deficiency due to growth hormone receptor deficiency: a controlled study in a genetically homogeneous population. 54 61
9626125 1998
34
Systemic and splanchnic metabolic response to exogenous human growth hormone. 54 61
9591005 1998
35
Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. 54 61
9467572 1998
36
Insulin-like growth factor I and its binding proteins 3 and 4 are increased in Human inflammatory synovial fluid. 54 61
8724290 1996
37
Insulin-like growth factor I resistance in immortalized T cell lines from African Efe Pygmies. 61 54
8530626 1995
38
Impaired growth in Rabson-Mendenhall syndrome: lack of effect of growth hormone and insulin-like growth factor-I. 61 54
8077364 1994
39
Disorders of growth hormone resistance in childhood. 61 54
8374676 1993
40
Insulin-like growth factor-I unresponsiveness in an Efe Pygmy. 54 61
8323544 1993
41
Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature. 54 61
1437400 1992
42
Assessment of growth hormone (GH) axis in Turner's syndrome using 24-hour integrated concentrations of GH, insulin-like growth factor-I, plasma GH-binding activity, GH binding to IM9 cells, and GH response to pharmacological stimulation. 61 54
1386373 1992
43
Gambogic Acid Affects Ribosomal Occurrence in Glioma Cells by Downregulating the Phosphoinositide Kinase-3/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway. 61
31748028 2020
44
Is soy protein effective in reducing cholesterol and improving bone health? 61
31848551 2019
45
Neurotrophic factors in the posterodorsal medial amygdala of male and cycling female rats. 61
31812781 2019
46
IGFBP-2 stimulates calcium/calmodulin-dependent protein kinase kinase 2 activation leading to AMP-activated protein kinase induction which is required for osteoblast differentiation. 61
31155724 2019
47
Associations between serum levels of insulin-like growth factor-I and bone mineral acquisition in pubertal children: a 3-year follow-up study in Hamamatsu, Japan. 61
31806017 2019
48
Correction to: Gene expression and DNA methylation changes in BeWo cells dependent on tumor necrosis factor-α and insulin-like growth factor-I. 61
31811568 2019
49
Gene expression and DNA methylation changes in BeWo cells dependent on tumor necrosis factor-α and insulin-like growth factor-I. 61
31724103 2019
50
Carthamus tinctorius L. extract activates insulin-like growth factor-I receptor signaling to inhibit FAS-death receptor pathway and suppress lipopolysaccharides-induced H9c2 cardiomyoblast cell apoptosis. 61
31486215 2019

Variations for Insulin-Like Growth Factor I

ClinVar genetic disease variations for Insulin-Like Growth Factor I:

6 (show top 50) (show all 340) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IGF1R NM_000875.5(IGF1R):c.413G>A (p.Arg138Gln)SNV protective 14790 rs121912426 15:99251109-99251109 15:98707880-98707880
2 IGF1R NM_000875.5(IGF1R):c.435A>C (p.Lys145Asn)SNV protective 14791 rs121912427 15:99251131-99251131 15:98707902-98707902
3 IGF1R NM_000875.5(IGF1R):c.265C>T (p.Arg89Ter)SNV protective 14792 rs121912428 15:99250961-99250961 15:98707732-98707732
4 IGF1R NM_000875.5(IGF1R):c.2216G>A (p.Arg739Gln)SNV protective 14793 rs121912429 15:99465391-99465391 15:98922162-98922162
5 IGF1R NM_000875.5(IGF1R):c.361G>A (p.Glu121Lys)SNV protective 446754 rs1555434208 15:99251057-99251057 15:98707828-98707828
6 IGF1R NM_000875.5(IGF1R):c.700G>A (p.Glu234Lys)SNV protective 446755 rs1253103806 15:99434613-99434613 15:98891384-98891384
7 IGF1R NM_000875.5(IGF1R):c.119G>T (p.Arg40Leu)SNV protective 446756 rs1409058783 15:99250815-99250815 15:98707586-98707586
8 IGF1R NM_000875.5(IGF1R):c.2201G>T (p.Arg734Ile)SNV protective 446757 rs1555460945 15:99460105-99460105 15:98916876-98916876
9 IGF1R NM_000875.5(IGF1R):c.384T>C (p.Ile128=)SNV Pathogenic 635841 15:99251080-99251080 15:98707851-98707851
10 IGF1R NM_000875.5(IGF1R):c.904G>T (p.Glu302Ter)SNV Pathogenic 635842 15:99434817-99434817 15:98891588-98891588
11 IGF1R NM_000875.5(IGF1R):c.3454G>A (p.Gly1152Arg)SNV Pathogenic 635846 15:99482586-99482586 15:98939357-98939357
12 IGF1R NM_000875.5(IGF1R):c.1247+1dupduplication Pathogenic 635844 15:99442851-99442852 15:98899622-98899623
13 IGF1 IGF1, EX4-5DELdeletion Pathogenic 14787
14 IGF1 IGF1, MUTATION IN POLYADENYLATION SIGNAL, T-ASNV Pathogenic 14788
15 IGF1 NM_001111283.3(IGF1):c.274G>A (p.Val92Met)SNV Pathogenic 14789 rs121912430 12:102813415-102813415 12:102419637-102419637
16 IGF1 NM_001111283.3(IGF1):c.292C>T (p.Arg98Trp)SNV Pathogenic 127243 rs587779350 12:102813397-102813397 12:102419619-102419619
17 IGF1R NM_000875.5(IGF1R):c.118C>T (p.Arg40Cys)SNV Likely pathogenic 635840 15:99250814-99250814 15:98707585-98707585
18 IGF1R NM_000875.5(IGF1R):c.3530G>A (p.Arg1177His)SNV Likely pathogenic 635848 15:99486224-99486224 15:98942995-98942995
19 IGF1R NM_000875.5(IGF1R):c.3539C>A (p.Ser1180Tyr)SNV Likely pathogenic 635847 15:99486233-99486233 15:98943004-98943004
20 IGF1R NM_000875.5(IGF1R):c.995G>A (p.Cys332Tyr)SNV Likely pathogenic 635843 15:99440027-99440027 15:98896798-98896798
21 IGF1R NM_000875.5(IGF1R):c.3162G>A (p.Met1054Ile)SNV Likely pathogenic 635845 15:99478258-99478258 15:98935029-98935029
22 IGF1R NM_000875.5(IGF1R):c.225C>T (p.Phe75=)SNV Conflicting interpretations of pathogenicity 281171 rs55770488 15:99250921-99250921 15:98707692-98707692
23 IGF1R NM_000875.5(IGF1R):c.1950G>T (p.Arg650=)SNV Conflicting interpretations of pathogenicity 282215 rs56294552 15:99459314-99459314 15:98916085-98916085
24 IGF1R NM_000875.5(IGF1R):c.*2426deldeletion Conflicting interpretations of pathogenicity 317531 rs398028512 15:99503097-99503097 15:98959868-98959868
25 IGF1R NM_000875.5(IGF1R):c.*3199C>TSNV Uncertain significance 317549 rs886051592 15:99503870-99503870 15:98960641-98960641
26 IGF1R NM_000875.5(IGF1R):c.*3338G>ASNV Uncertain significance 317552 rs532358446 15:99504009-99504009 15:98960780-98960780
27 IGF1R NM_000875.5(IGF1R):c.*3440G>ASNV Uncertain significance 317554 rs146062117 15:99504111-99504111 15:98960882-98960882
28 IGF1R NM_000875.5(IGF1R):c.*3616C>GSNV Uncertain significance 317563 rs138949122 15:99504287-99504287 15:98961058-98961058
29 IGF1R NM_000875.5(IGF1R):c.*3731dupduplication Uncertain significance 317565 rs375868122 15:99504402-99504402 15:98961173-98961173
30 IGF1R NM_000875.5(IGF1R):c.*3999A>GSNV Uncertain significance 317569 rs567405313 15:99504670-99504670 15:98961441-98961441
31 IGF1R NM_000875.5(IGF1R):c.*4521G>ASNV Uncertain significance 317584 rs560705462 15:99505192-99505192 15:98961963-98961963
32 IGF1R NM_000875.5(IGF1R):c.*4599C>TSNV Uncertain significance 317586 rs144947320 15:99505270-99505270 15:98962041-98962041
33 IGF1R NM_000875.5(IGF1R):c.*4761C>TSNV Uncertain significance 317590 rs572204649 15:99505432-99505432 15:98962203-98962203
34 IGF1R NM_000875.5(IGF1R):c.*4815G>ASNV Uncertain significance 317593 rs145781849 15:99505486-99505486 15:98962257-98962257
35 IGF1R NM_000875.5(IGF1R):c.*5152T>GSNV Uncertain significance 317600 rs886051602 15:99505823-99505823 15:98962594-98962594
36 IGF1R NM_000875.5(IGF1R):c.*4186A>GSNV Uncertain significance 317573 rs565316919 15:99504857-99504857 15:98961628-98961628
37 IGF1R NM_000875.5(IGF1R):c.*5428A>GSNV Uncertain significance 317603 rs138827688 15:99506099-99506099 15:98962870-98962870
38 IGF1 NM_001111283.3(IGF1):c.*1758C>TSNV Uncertain significance 306894 rs6212 12:102794561-102794561 12:102400783-102400783
39 IGF1 NM_001111283.3(IGF1):c.*1353A>GSNV Uncertain significance 306897 rs765196070 12:102794966-102794966 12:102401188-102401188
40 IGF1R NM_000875.5(IGF1R):c.641-14C>TSNV Uncertain significance 317440 rs200261849 15:99434540-99434540 15:98891311-98891311
41 IGF1R NM_000875.5(IGF1R):c.3594C>T (p.Phe1198=)SNV Uncertain significance 317458 rs35701313 15:99491809-99491809 15:98948580-98948580
42 IGF1R NM_000875.5(IGF1R):c.4069C>T (p.Arg1357Trp)SNV Uncertain significance 317463 rs143940675 15:99500636-99500636 15:98957407-98957407
43 IGF1R NM_000875.5(IGF1R):c.*43G>ASNV Uncertain significance 317465 rs56403719 15:99500714-99500714 15:98957485-98957485
44 IGF1R NM_000875.5(IGF1R):c.*63_*64AG[3]short repeat Uncertain significance 317471 rs370196264 15:99500740-99500741 15:98957511-98957512
45 IGF1R NM_000875.5(IGF1R):c.*149C>TSNV Uncertain significance 317473 rs886051563 15:99500820-99500820 15:98957591-98957591
46 IGF1R NM_000875.5(IGF1R):c.*199C>TSNV Uncertain significance 317474 rs886051564 15:99500870-99500870 15:98957641-98957641
47 IGF1 NM_001111283.3(IGF1):c.*296_*297AT[10]short repeat Uncertain significance 306902 rs201878788 12:102796006-102796007 12:102402228-102402229
48 IGF1 NM_001111283.3(IGF1):c.*6656A>GSNV Uncertain significance 306827 rs537246408 12:102789663-102789663 12:102395885-102395885
49 IGF1R NM_000875.5(IGF1R):c.*837C>TSNV Uncertain significance 317489 rs886051569 15:99501508-99501508 15:98958279-98958279
50 IGF1R NM_000875.5(IGF1R):c.*866dupduplication Uncertain significance 317490 rs886051570 15:99501537-99501537 15:98958308-98958308

UniProtKB/Swiss-Prot genetic disease variations for Insulin-Like Growth Factor I:

73
# Symbol AA change Variation ID SNP ID
1 IGF1R p.Arg138Gln VAR_034891 rs121912426
2 IGF1R p.Lys145Asn VAR_034892 rs121912427
3 IGF1R p.Arg739Gln VAR_034895 rs121912429
4 IGF1R p.Asn359Tyr VAR_076247
5 IGF1R p.Tyr865Cys VAR_076248
6 IGF1R p.Arg1256Ser VAR_076249
7 IGF1R p.Arg1337Cys VAR_076250 rs141802822

Expression for Insulin-Like Growth Factor I

Search GEO for disease gene expression data for Insulin-Like Growth Factor I.

Pathways for Insulin-Like Growth Factor I

Pathways related to Insulin-Like Growth Factor I according to KEGG:

36
# Name Kegg Source Accession
1 PI3K-Akt signaling pathway hsa04151
2 Oocyte meiosis hsa04114
3 Focal adhesion hsa04510
4 Adherens junction hsa04520
5 Long-term depression hsa04730
6 Progesterone-mediated oocyte maturation hsa04914

Pathways related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 ITGB3 ITGAV ITGA6 INSR INS IGF2
2
Show member pathways
13.92 ITGB3 ITGAV ITGA6 IRS1 INSR IGF2
3
Show member pathways
13.88 INS IGFBP6 IGFBP5 IGFBP4 IGFBP3 IGFBP2
4
Show member pathways
13.79 ITGB3 ITGAV ITGA6 INSR IGF2 IGF1R
5
Show member pathways
13.55 ITGB3 ITGAV ITGA6 IRS1 INSR INS
6
Show member pathways
13.49 ITGB3 ITGAV ITGA6 IRS1 INSR IGF2
7
Show member pathways
13.39 ITGB3 ITGAV ITGA6 IGF2 IGF1 AKT2
8
Show member pathways
13.31 IRS1 IGF2 IGF1R IGF1 GHR GH1
9
Show member pathways
13.17 ITGB3 ITGAV ITGA6 IGF2 IGF1R IGF1
10
Show member pathways
13.15 IRS1 INSR INS IGF2 IGF1R IGF1
11
Show member pathways
13.03 IRS1 IGF2 IGF1R IGF1 AKT2 AKT1
12
Show member pathways
13.01 ITGB3 ITGAV ITGA6 INSR IGF1R
13
Show member pathways
13.01 ITGB3 ITGAV ITGA6 IGF1R IGF1 AKT2
14
Show member pathways
12.96 IRS1 INS IGF1R IGF1 AKT2 AKT1
15 12.96 ITGAV ITGA6 IGF2 IGF1R IGF1 AKT2
16
Show member pathways
12.92 ITGB3 ITGAV ITGA6 IRS1 INSR INS
17 12.88 INSR INS IGF2 IGF1R IGF1 AKT2
18
Show member pathways
12.87 IGF2 IGF1R IGF1 AKT2 AKT1
19
Show member pathways
12.85 IRS1 INSR INS AKT2 AKT1
20
Show member pathways
12.84 ITGB3 INSR INS IGF2 IGF1R IGF1
21
Show member pathways
12.84 IRS1 INSR INS IGFBP3 IGF1R IGF1
22
Show member pathways
12.83 IGF2 IGF1R IGF1 AKT2 AKT1
23
Show member pathways
12.8 IRS1 INSR INS AKT2 AKT1
24
Show member pathways
12.8 ITGB3 ITGAV ITGA6 IRS1 INSR INS
25
Show member pathways
12.79 IRS1 IGFBP3 IGF1 GHR GH1 AKT2
26
Show member pathways
12.76 ITGB3 ITGAV ITGA6 IRS1 INSR IGF2
27
Show member pathways
12.75 IRS1 IGF1R IGF1 AKT2 AKT1
28
Show member pathways
12.66 IRS1 IGF1R IGF1 AKT2 AKT1
29
Show member pathways
12.66 IGFBP6 IGFBP5 IGFBP4 IGFBP3 IGFBP2 IGFBP1
30
Show member pathways
12.65 IRS1 INSR INS IGF1R AKT2 AKT1
31
Show member pathways
12.64 ITGB3 ITGAV AKT2 AKT1
32
Show member pathways
12.64 IRS1 INSR INS AKT2 AKT1
33
Show member pathways
12.62 IRS1 INSR INS IGF1R IGF1 AKT2
34
Show member pathways
12.59 ITGB3 ITGAV ITGA6 IRS1 AKT1
35
Show member pathways
12.58 IRS1 INS GH1 AKT2 AKT1
36
Show member pathways
12.54 ITGAV INSR IGF1R AKT2 AKT1
37
Show member pathways
12.54 IRS1 INSR INS IGF1R IGF1 AKT2
38
Show member pathways
12.5 ITGB3 ITGAV ITGA6 INSR IGF2 IGF1R
39
Show member pathways
12.47 INSR INS AKT2 AKT1
40
Show member pathways
12.47 INS IGF1R IGF1 AKT2 AKT1
41
Show member pathways
12.46 ITGB3 ITGAV AKT2 AKT1
42
Show member pathways
12.44 IRS1 INSR IGF1R IGF1 AKT2 AKT1
43
Show member pathways
12.42 GHR GH1 AKT2 AKT1
44 12.4 IRS1 INSR INS IGFBP3 IGFBP2 IGFBP1
45 12.38 ITGB3 ITGAV IGF2 IGF1R IGF1 AKT2
46
Show member pathways
12.36 IGF2 IGF1R IGF1 GH1 AKT1
47
Show member pathways
12.35 ITGB3 ITGAV ITGA6 INSR IGF1R AKT2
48
Show member pathways
12.34 IRS1 IGF1R IGF1 AKT2 AKT1
49
Show member pathways
12.33 ITGB3 ITGAV ITGA6 IGF1
50
Show member pathways
12.33 IRS1 INSR INS AKT2 AKT1

GO Terms for Insulin-Like Growth Factor I

Cellular components related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.14 INS IGFBP6 IGFBP5 IGFBP4 IGFBP3 IGFBP2
2 extracellular space GO:0005615 10.06 INS IGFBP6 IGFBP5 IGFBP4 IGFBP3 IGFBP2
3 external side of plasma membrane GO:0009897 9.95 LRP2 ITGAV ITGA6 INSR GHR
4 endoplasmic reticulum lumen GO:0005788 9.93 INS IGFBP5 IGFBP4 IGFBP3 IGFBP1
5 receptor complex GO:0043235 9.83 LRP2 ITGB3 INSR IGF1R GHR
6 integrin complex GO:0008305 9.67 ITGB3 ITGAV ITGA6
7 endosome lumen GO:0031904 9.54 LRP2 INS GH1
8 alphav-beta3 integrin-HMGB1 complex GO:0035868 9.52 ITGB3 ITGAV
9 alphav-beta3 integrin-PKCalpha complex GO:0035866 9.51 ITGB3 ITGAV
10 growth hormone receptor complex GO:0070195 9.48 GHR GH1
11 integrin alphav-beta3 complex GO:0034683 9.46 ITGB3 ITGAV
12 insulin receptor complex GO:0005899 9.43 IRS1 INSR IGF1R
13 insulin-like growth factor ternary complex GO:0042567 9.33 IGFBP5 IGFBP3 IGF1
14 insulin-like growth factor binding protein complex GO:0016942 9.13 IGFBP5 IGFBP3 IGF1
15 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0035867 8.92 ITGB3 ITGAV IGF1R IGF1

Biological processes related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.3 IRS1 INS IGFBP6 IGFBP5 IGFBP4 IGFBP2
2 negative regulation of apoptotic process GO:0043066 10.14 LRP2 IGF1R IGF1 AKT2 AKT1
3 positive regulation of cell proliferation GO:0008284 10.13 ITGAV IRS1 INSR INS IGF2 IGF1R
4 carbohydrate metabolic process GO:0005975 10.05 INSR INS IGF2 AKT2 AKT1
5 positive regulation of cell migration GO:0030335 10.05 ITGAV ITGA6 INSR INS IGF1R IGF1
6 positive regulation of protein phosphorylation GO:0001934 10.02 ITGB3 INSR IGF2 AKT2 AKT1
7 positive regulation of protein kinase B signaling GO:0051897 10 LRP2 IRS1 INSR INS IGFBP5 IGF2
8 negative regulation of canonical Wnt signaling pathway GO:0090090 9.99 IGFBP6 IGFBP4 IGFBP2 IGFBP1
9 aging GO:0007568 9.99 IGFBP5 IGFBP2 IGFBP1 AKT1
10 positive regulation of MAPK cascade GO:0043410 9.98 INSR INS IGFBP4 IGFBP3 IGF2 IGF1R
11 cellular response to insulin stimulus GO:0032869 9.97 IRS1 INSR GHR AKT2 AKT1
12 glucose homeostasis GO:0042593 9.97 IRS1 INSR INS IGFBP5 IGF1R AKT1
13 osteoblast differentiation GO:0001649 9.96 IGFBP5 IGFBP3 IGF2 AKT1
14 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.96 ITGB3 IGF2 IGF1 GHR GH1
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.95 INSR INS IGF1R IGF1 GH1
16 regulation of growth GO:0040008 9.93 IGFBP5 IGFBP4 IGFBP3 IGFBP2
17 glucose metabolic process GO:0006006 9.91 INS IGF2 AKT2 AKT1
18 cellular protein metabolic process GO:0044267 9.91 INS IGFBP6 IGFBP5 IGFBP4 IGFBP3 IGFBP2
19 positive regulation of cell growth GO:0030307 9.9 INS IGFBP1 AKT1
20 regulation of cell growth GO:0001558 9.89 IGFBP5 IGFBP4 IGFBP3
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 IGF1 GHR GH1
22 cellular response to growth factor stimulus GO:0071363 9.88 LRP2 INSR AKT1
23 cellular response to organic cyclic compound GO:0071407 9.88 ITGA6 IGFBP5 AKT1
24 activation of protein kinase B activity GO:0032148 9.88 INSR INS IGF1 AKT1
25 phosphatidylinositol 3-kinase signaling GO:0014065 9.88 IRS1 IGF1R IGF1 AKT1
26 regulation of protein localization GO:0032880 9.87 ITGB3 INS AKT1
27 phosphatidylinositol-mediated signaling GO:0048015 9.87 IRS1 IGF1R IGF1
28 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.85 ITGAV ITGA6 IGF1
29 positive regulation of multicellular organism growth GO:0040018 9.85 IGF2 GHR GH1
30 positive regulation of mitotic nuclear division GO:0045840 9.84 INSR INS IGF2 IGF1
31 positive regulation of activated T cell proliferation GO:0042104 9.83 IGFBP2 IGF2 IGF1
32 positive regulation of insulin receptor signaling pathway GO:0046628 9.82 IRS1 INS IGF2
33 positive regulation of glycolytic process GO:0045821 9.82 INSR INS IGF1
34 striated muscle cell differentiation GO:0051146 9.81 IGFBP5 IGF2 AKT1
35 cell-substrate adhesion GO:0031589 9.8 ITGB3 ITGAV ITGA6
36 insulin-like growth factor receptor signaling pathway GO:0048009 9.8 IRS1 IGF1R IGF1 GHR AKT1
37 positive regulation of glucose import GO:0046326 9.8 IRS1 INSR INS IGF1 AKT2 AKT1
38 response to growth hormone GO:0060416 9.79 IGFBP5 GHR AKT1
39 amyloid-beta clearance GO:0097242 9.79 LRP2 INSR IGF1R
40 type B pancreatic cell proliferation GO:0044342 9.77 IGFBP5 IGFBP4 IGFBP3
41 positive regulation of glucose metabolic process GO:0010907 9.77 IRS1 AKT2 AKT1
42 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.77 IGFBP5 IGFBP4 IGFBP3 IGF1 GH1
43 insulin receptor signaling pathway GO:0008286 9.76 IRS1 INSR INS IGFBP1 IGF2 IGF1R
44 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.74 INS AKT1
45 mammary gland epithelial cell differentiation GO:0060644 9.73 AKT2 AKT1
46 positive regulation of lipid biosynthetic process GO:0046889 9.73 INS AKT1
47 transcytosis GO:0045056 9.73 LRP2 IGF1R
48 negative regulation of smooth muscle cell migration GO:0014912 9.73 IGFBP5 IGFBP3
49 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.73 ITGB3 ITGAV
50 growth hormone receptor signaling pathway GO:0060396 9.73 GHR GH1

Molecular functions related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.43 LRP2 ITGB3 ITGAV ITGA6 IRS1 INSR
2 signaling receptor binding GO:0005102 9.96 ITGAV IGFBP6 IGFBP4 IGFBP2 IGFBP1
3 integrin binding GO:0005178 9.83 ITGB3 ITGAV IGF2 IGF1
4 hormone activity GO:0005179 9.8 INS IGF2 IGF1 GH1
5 fibronectin binding GO:0001968 9.8 ITGB3 ITGAV IGFBP6 IGFBP5 IGFBP3
6 growth factor binding GO:0019838 9.8 IGFBP6 IGFBP5 IGFBP4 IGFBP3 IGFBP2 IGFBP1
7 insulin receptor binding GO:0005158 9.77 IRS1 INS IGF2 IGF1R IGF1
8 protein kinase C binding GO:0005080 9.74 ITGAV IRS1 AKT1
9 insulin-like growth factor receptor binding GO:0005159 9.72 IRS1 INSR INS IGF2 IGF1
10 insulin-like growth factor II binding GO:0031995 9.7 INSR IGFBP6 IGFBP5 IGFBP4 IGFBP3 IGFBP2
11 phosphatidylinositol 3-kinase binding GO:0043548 9.65 IRS1 INSR IGF1R
12 neuregulin binding GO:0038132 9.61 ITGB3 ITGAV ITGA6
13 insulin receptor substrate binding GO:0043560 9.58 INSR IGF1R
14 insulin binding GO:0043559 9.55 INSR IGF1R
15 C-X3-C chemokine binding GO:0019960 9.54 ITGB3 ITGAV
16 insulin-activated receptor activity GO:0005009 9.51 INSR IGF1R
17 insulin-like growth factor binding GO:0005520 9.5 IGFBP6 IGFBP5 IGFBP4 IGFBP3 IGFBP2 IGFBP1
18 insulin-like growth factor I binding GO:0031994 9.4 LRP2 ITGB3 ITGAV ITGA6 INSR IGFBP6

Sources for Insulin-Like Growth Factor I

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
47